Renal transplantation Urological and Genital Diseases Renal transplantation
Conditions
Interventions
Renal denervation as a treatment for hypertension, performed to the native renal arteries.
Updated 28/05/2014: this trial was stopped due to lack of funding.
Sponsors
NHS Greater Glasgow and Clyde (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 18?85 years, either sex, with a clinic systolic blood pressure of 140 mmHg or more, despite compliance with two or more antihypertensive drugs, are eligible for inclusion 2. Patients should be >12 months post renal transplantation with no evidence of rejection in past 3 months and doses of immunosuppression should be stable for >6 weeks prior to study entry
Exclusion criteria
Exclusion criteria: 1. Inability to give informed consent 2. Contraindications to MRI imaging (pacemaker, extreme claustrophobia) 3. Pregnancy and breastfeeding 4. Impaired transplant kidney function (estimated glomerular filtration rate [GFR] <30 ml/min) 5. Known secondary cause of hypertension other than renal disease (e.g. Conn's syndrome, Phaeochromocytoma etc)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point will be systolic blood pressure on 24-hour ambulatory blood pressure monitor | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Left ventricular mass index at cardiac MRI scan at 6 months following RDN 2. Diastolic blood pressure on 24-hour ambulatory blood pressure monitor 3. Number of antihypertensive agents used 4. Renal function by estimated GFR 5. Urinary protein estimation by urinary protein: creatinine ratio | — |
Countries
United Kingdom
Outcome results
None listed